Title:Efficacy of Sinopharm Vaccine Among Stem Cell Transplant Recipients
During Two Peaks of Delta and Omicron variants of COVID-19
Volume: 18
Issue: 4
Author(s): Ali Ghasemi, Rozita Khodashahi*, Mohsen Aliakbarian, Ebrahim Khaleghi, Baran Razmkhah, Mehrsa Vahdatinia, Mahdi Salimi Far and Omolbanin Bakhti
Affiliation:
- Mashhad Transplant Research Center, Montaserieh Hospital, Mashhad University of Medical
Sciences, Mashhad, Iran
- Clinical Research Development Unit, Imam Reza Hospital, Faculty of Medicine, Mashhad University
of Medical Sciences, Mashhad, Iran
- Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine,
Mashhad University of Sciences, Mashhad, Iran
Keywords:
COVID-19, side effects, transplant, vaccination, sinopharm, stem cell.
Abstract:
Background: Considering the dearth of research on the complications of Sinopharm
coronavirus disease 2019 (COVID-19) vaccine in immunocompromised individuals and the lack of
available data on COVID-19 vaccination from Iran.
Objective: This study aimed to investigate the efficacy of vaccine of Sinopharm COVID-19 vaccine
and its complications in bone marrow transplant (BMT) recipients.
Methods: This was a retrospective cross-sectional study conducted on 250 patients with BMT who
were referred to Montaserieh Hospital, Mashhad, Iran. Among them, 53 cases who received at least
two doses of Sinopharm COVID-19 vaccine from March to January 2021 were entered in this
study. The data were extracted from a student dissertation (Code:4000370).
Results: Sinopharm vaccine side effects were reported only in 7.7% of the patients, and shingles
was the only serious side effect of the Sinopharm vaccine, which was observed only in one case.
The results also revealed that Sinopharm COVID-19 vaccine side effects were not related to age or
gender. Infection with the Delta variant of COVID-19 was reported in 7.5% (n=4) and no mortality
was reported among them. Vaccine failure was reported in 39.6% of the cases; however, no mortality
was reported among patients infected with the Omicron variant of COVID-19.
Conclusion: In summary, it seems that Sinopharm COVID-19 vaccine adverse effects were not serious
among stem cell transplant recipients. However, it may lead to some severe complications in
the population. Vaccine failure against the Delta and Omicron variants of COVID-19 has been reported
among more than one-third of BMT patients; however, no mortality was observed among
BMT patients infected with the new variants of COVID-19.
